( September 24, 2025, 2:39 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on Sept. 23 agreed with the U.S. Patent Trial and Appeal Board (PTAB) that some claims in a patent held by Bayer Pharma Aktiengesellschaft are unpatentable as obvious, but the panel vacated the board’s finding of obviousness for other claims, holding that it was based on an incorrect claim construction regarding the administration of aspirin in a cardiac medication regimen....